195 related articles for article (PubMed ID: 37286536)
1. The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users.
Shram MJ; Henningfield JE; Apseloff G; Gorodetzky CW; De Martin S; Vocci FL; Sapienza FL; Kosten TR; Huston J; Buchhalter A; Ashworth J; Lanier R; Folli F; Mattarei A; Guidetti C; Comai S; O'Gorman C; Traversa S; Inturrisi CE; Manfredi PL; Pappagallo M
Transl Psychiatry; 2023 Jun; 13(1):192. PubMed ID: 37286536
[TBL] [Abstract][Full Text] [Related]
2. Abuse Potential of Samidorphan: A Phase I, Oxycodone-, Pentazocine-, Naltrexone-, and Placebo-Controlled Study.
Pathak S; Vince B; Kelsh D; Setnik B; Nangia N; DiPetrillo L; Puhl MD; Sun L; Stanford AD; Ehrich E
J Clin Pharmacol; 2019 Feb; 59(2):218-228. PubMed ID: 30476361
[TBL] [Abstract][Full Text] [Related]
3. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.
Setnik B; Schoedel K; Bartlett C; Dick C; Hakim N; Geoffroy P
J Opioid Manag; 2017; 13(6):449-464. PubMed ID: 29308591
[TBL] [Abstract][Full Text] [Related]
4. Human Abuse Potential of Oral NKTR-181 in Recreational Opioid Users: A Randomized, Double-Blind, Crossover Study.
Ge X; Henningfield JE; Siddhanti S; Jobes J; Lu L; Xie S; Ziola M; Kelsh D; Vince B; Di Fonzo CJ; Tagliaferri M; Zalevsky J; Doberstein SK; Hoch U; Eldon MA
Pain Med; 2020 Feb; 21(2):e114-e126. PubMed ID: 31553457
[TBL] [Abstract][Full Text] [Related]
5. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial.
Schoedel KA; Szeto I; Setnik B; Sellers EM; Levy-Cooperman N; Mills C; Etges T; Sommerville K
Epilepsy Behav; 2018 Nov; 88():162-171. PubMed ID: 30286443
[TBL] [Abstract][Full Text] [Related]
6. Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users.
Backonja M; Webster LR; Setnik B; Bass A; Sommerville KW; Matschke K; Malhotra BK; Wolfram G
Am J Drug Alcohol Abuse; 2016 Sep; 42(5):539-549. PubMed ID: 27211522
[TBL] [Abstract][Full Text] [Related]
7. Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with Oxycodone.
Webster L; Henningfield J; Buchhalter AR; Siddhanti S; Lu L; Odinecs A; Di Fonzo CJ; Eldon MA
Pain Med; 2018 Feb; 19(2):307-318. PubMed ID: 28340145
[TBL] [Abstract][Full Text] [Related]
8. REL-1017 (esmethadone; D-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats.
Henningfield J; Gauvin D; Bifari F; Fant R; Shram M; Buchhalter A; Ashworth J; Lanier R; Pappagallo M; Inturrisi C; Folli F; Traversa S; Manfredi PL
Sci Rep; 2022 Jul; 12(1):11389. PubMed ID: 35794162
[TBL] [Abstract][Full Text] [Related]
9. A nasal abuse potential randomized clinical trial of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.
Friedmann N; Marsman MR; de Kater AW; Burns LH; Webster LR
J Opioid Manag; 2018; 14(6):437-443. PubMed ID: 30629280
[TBL] [Abstract][Full Text] [Related]
10. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users.
Harris SC; Perrino PJ; Smith I; Shram MJ; Colucci SV; Bartlett C; Sellers EM
J Clin Pharmacol; 2014 Apr; 54(4):468-77. PubMed ID: 24243216
[TBL] [Abstract][Full Text] [Related]
11. Drug-Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism.
Ferri N; De Martin S; Stuart J; Traversa S; Folli F; Pappagallo M; O'Gorman C; Guidetti C; Mattarei A; Inturrisi CE; Manfredi PL
Drugs R D; 2024 Mar; 24(1):51-68. PubMed ID: 38010591
[TBL] [Abstract][Full Text] [Related]
12. Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users.
Setnik B; Bramson C; Bass A; Levy-Cooperman N; Malhotra B; Matschke K; Sommerville KW; Wolfram G; Geoffroy P
J Clin Pharmacol; 2015 Dec; 55(12):1351-61. PubMed ID: 26011742
[TBL] [Abstract][Full Text] [Related]
13. Abuse liability assessment of eslicarbazepine acetate in healthy male and female recreational sedative users: A Phase I randomized controlled trial.
Levy-Cooperman N; Schoedel KA; Chakraborty B; Blum D; Cheng H
Epilepsy Behav; 2016 Aug; 61():63-71. PubMed ID: 27315134
[TBL] [Abstract][Full Text] [Related]
14. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent Formulation.
Webster LR; Iverson M; Pantaleon C; Smith MD; Kinzler ER; Aigner S
Pain Med; 2019 Apr; 20(4):747-757. PubMed ID: 29608768
[TBL] [Abstract][Full Text] [Related]
15. Human abuse potential of brivaracetam in healthy recreational central nervous system depressant users.
Schoedel KA; Stockis A; Sellers EM
Epilepsy Behav; 2018 Jan; 78():194-201. PubMed ID: 29153631
[TBL] [Abstract][Full Text] [Related]
16. Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta™) tablets in nondependent recreational opioid users.
Schoedel KA; Rolleri RL; Faulknor JY; Pixton GC; Chen N; Bass A; Sommerville KW; Sellers E
J Opioid Manag; 2012; 8(5):315-27. PubMed ID: 23247908
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind, placebo-controlled and active-controlled study to assess the relative abuse potential of oxycodone HCl-niacin tablets compared with oxycodone alone in nondependent, recreational opioid users.
Webster LR; Rolleri RL; Pixton GC; Sommerville KW
Subst Abuse Rehabil; 2012; 3():101-13. PubMed ID: 24474870
[TBL] [Abstract][Full Text] [Related]
18. Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem.
Ufer M; Kelsh D; Schoedel KA; Dingemanse J
Sleep; 2022 Mar; 45(3):. PubMed ID: 34480579
[TBL] [Abstract][Full Text] [Related]
19. Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users.
Setnik B; Bass A; Bramson C; Levy-Cooperman N; Malhotra B; Matschke K; Geoffroy P; Sommerville KW; Wolfram G
Pain Med; 2017 Jun; 18(6):1077-1088. PubMed ID: 27550954
[TBL] [Abstract][Full Text] [Related]
20. Measurement of Drug Liking in Abuse Potential Studies: A Comparison of Unipolar and Bipolar Visual Analog Scales.
Setnik B; Roland CL; Pixton G; Webster L
J Clin Pharmacol; 2017 Feb; 57(2):266-274. PubMed ID: 27444046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
